A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Clinical trial NCT01316263 · TERMINATED

Trial details

NCT number: NCT01316263
Sponsor: Eli Lilly and Company
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Gastrointestinal Stromal Tumor (GIST)

Start date: 2011-08-01
Primary completion: 2012-05-01
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.